More than 1.2 million people died in 2019 from infections caused by bacteria resistant to multiple antibiotics, higher than HIV/AIDS or malaria, according to a new report published on January 20.

Engitix Therapeutics raised $54 million in Series A financing. Engitix plans to use the money to boost the company’s drug discovery pipeline in fibrosis and cancer and expand its team, facilities and operations.

When used in children, rapid antigen tests for detecting the coronavirus do not meet accuracy criteria set by the World Health Organization and U.S. and UK device regulators, according to researchers who reviewed 17 studies of the tests. Other research appears to confirm smaller, earlier studies that suggested nursing mothers are unlikely to transmit the coronavirus in breastmilk.

Ceptur Therapeutics – based in Hillsborough, NJ, Philadelphia and Copenhagen – closed on a Series A financing round worth $75 million.

Valneva said on January 19 that preliminary studies showed three doses of the French biotech firm’s inactivated COVID-19 vaccine candidate neutralized the Omicron variant of the disease.

The U.S. government will make 400 million non-surgical N95 masks from its strategic national stockpile available for free to the public starting next week, a White House official said, marking the Biden administration’s latest effort to help curb the COVID-19 pandemic.